REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress – PRNewswire

Posted: October 17, 2019 at 4:50 pm

ROCKVILLE, Md., Oct. 17, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced the presentation of two posters at the European Society of Gene & Cell Therapy (ESGCT) 27th Annual Congress in Barcelona, Spain, taking place from October 22 to 25, 2019.

The data will be presented as follows:

Abstract Title: Characterization of a Novel AAV Capsid with Enhanced Brain Transduction Following Systemic Delivery (poster #P011)Presenter: Subha Karumuthil-Melethil, Ph.D., Senior Scientist, Target Discovery, REGENXBIOSession Title: Poster Session IDate/Time: Wednesday, October 23, 2019, 1:00 p.m. to 3:00 p.m. CESTLocation:Multipurpose Hall P011

Abstract Title: AAV9.hCLN2 (RGX-181) Improves Survival and Neuropathology in TPP1m1J Mice, a Model for CLN2 Batten Disease (poster #P018)Presenter: Nicholas Buss, Ph.D., Director, Preclinical Development, REGENXBIOSession Title: Poster Session II Date/Time: Thursday, October 24, 2019, 1:15 p.m. to 2:45 p.m. CESTLocation:Multipurpose Hall P018

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas. For more information, visit http://www.regenxbio.com.

Contacts:Tricia TruehartInvestor Relations and Corporate Communications347-926-7709ttruehart@regenxbio.com

Investors:Heather Savelle, 212-600-1902heather@argotpartners.com

Media:David Rosen, 212-600-1902david.rosen@argotpartners.com

SOURCE REGENXBIO Inc.

http://www.regenxbio.com

See the article here:
REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress - PRNewswire

Related Posts